Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Caelyx

National Institute for Health and Care Excellence NICE logo

NICE wants more info on Genzyme’s MS drug

UK health guidance body turns down Lemtrada in draft guidance

National Institute for Health and Care Excellence NICE logo

NICE backs two eye treatments

Novartis’ Lucentis and Alimera’s Iluvien received green light for NHS use

- PMLiVE

Scotland first in UK to back Pfizer’s Inlyta

SMC also recommends Astellas' Xtandi but not Pfizer's Bosulif

National Institute for Health and Care Excellence NICE logo

NICE denies early use of Janssen’s Velcade

Draft guidance doesn't recommend expanded bone marrow cancer indication

- PMLiVE

Pfizer slams UK drug pricing plan

BioIndustry Association 
also challenges revision to PPRS

UK flag

NHS medicine spend to remain flat for two years

But UK drug pricing deal stops short of PPRS overhaul to value-based system

- PMLiVE

Late-stage ovarian cancer

Novel treatment strategies have yielded several promising agents that have reached phase III

- PMLiVE

Novartis’ Lucentis wins fourth NICE recommendation

But eye drug only recommended after a price-cutting patient access scheme offered

- PMLiVE

Celgene’s Revlimid knocked-back by NICE

Final draft guidance from NICE does not recommend drug for rare bone marrow disorder

Novartis building

NICE backs Novartis/ ThromboGenics’ eye drug

Recommends Jetrea for NHS use in England and Wales to treat the rare disease vitreomacular traction

- PMLiVE

Astellas wins NICE backing for Xtandi in prostate cancer

England’s health guidance body says drug can be used in advanced cases of the disease

- PMLiVE

Merck’s vintafolide shows its worth in ovarian cancer

Phase II data shows improvement on current oncology treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links